Progression‐free survival (PFS) in patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) is limited due to acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib,1 and investigations of the molecular mechanisms underlying resistance to EGFR‐TKI are performed globally. Here, EGFR is linked to lung cancer.